Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017


News SummaryMost relevantAll newsSector newsTweets 

Pfizer CEO: spin-off more likely for animal health

share with twitter share with LinkedIn share with facebook
share via e-mail
03/12/2012 | 03:47pm CEST

Pfizer Inc (>> Pfizer Inc.) is more likely to spin off its animal health unit than sell it outright, reflecting the expected investor appeal of such a large standalone business, its chief executive said on Monday.

Pfizer Inc (>> Pfizer Inc.) is more likely to spin off its animal health unit than sell it outright, reflecting the expected investor appeal of such a large standalone business, its chief executive said on Monday.

No final decision has been taken but Ian Read told Reuters there were clear attractions for shareholders in a tax-free spinoff of the operation, which is the biggest in the industry.

"I would probably handicap animal health as more likely to be a spin than a sale," the CEO of the world's biggest drugmaker said in an interview in London.

Read, who took over as Pfizer chief in December 2010 at a challenging time, is shrinking the group by divesting non-core businesses, including veterinary medicine and infant nutrition.

Pfizer is losing billions of dollars of revenue from cholesterol blockbuster Lipitor, which is now off patent in many markets, although Read said he hopes to carve out a new future for the medicine as an over-the-counter (OTC) product.

The nutrition business is widely expected to be sold outright for around $10 billion. Bidders were asked to submit offers last week, with Nestle SA (>> Nestle SA) and a partnership of Danone SA and Mead Johnson Nutrition Co (>> Mead Johnson Nutrition CO) seen as frontrunners.

The process for animal health, however, is less well advanced and the case for a sale less obvious. Pfizer faces a hefty tax bill if it sells outright and any buyer would also faces substantial antitrust hurdles.

"It's the largest animal health business and it would stand alone as an individual company. There's huge interest among investors to own a company like that," Read said.

"With nutritional there are lots of companies that are already in the nutritional business and have it as a major development area."

Speculation about a possible sale of animal health, which analysts believe could be worth $15-20 billion, was fuelled last week by reports that Novartis AG (>> Novartis AG) had made an approach that was rebuffed by Pfizer, while Bayer AG (>> Bayer AG) was also weighing a move.

The plans to dispose of both units, which Pfizer has said would be completed between July 2012 and July 2013, follows a far-reaching review and a decision to focus on core pharmaceutical operations.

The outcome of that review was to focus on five core areas of drug research, while maintaining a strong presence in generic and OTC medicines.

Read said Pfizer hoped to introduce a non-prescription form of Lipitor, but this would not happen in the short term. Pfizer is currently discussing the issue with the Food and Drug Administration, which is seeking public comment on the idea of making more medicines available OTC.

"We would like to sell it over the counter. We're in discussions and development with the FDA on that," Read said.

In the past, Pfizer has been a mergers and acquisitions machine, snapping up smaller rivals and partners to build out its portfolio.

It will continue to look for bolt-on acquisitions, including deals that could be "multiples" of 2010's $3.6 billion purchase of King Pharmaceuticals, Read said. But he did not see a need for another large-scale deal like the $67 billion purchase of Wyeth in 2009.

Asked about the possibility of buying out Bristol-Myers Squibb Co (>> Bristol Myers Squibb Co.), its partner on promising anti-clotting drug Eliquis, Read said: "I'm not sure that would create shareholder value. I think the partnership is working very well."

(Editing by Chris Wickham)

By Ben Hirschler and Kate Kelland

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BAYER
06/21 Sore Throat Remedies Market 2017 - Pfizer, Novartis, Bayer AG, AstraZeneca, P..
06/20 Novartis eye drug works with fewer injections than rival
06/20 COVESTRO : LLC President to Co-Lead Sustainable Pittsburgh’s ‘CEOs f..
06/18 BAYER : Selects Young Leaders to Help Address Global Food Security Challenges
06/15 BAYER : Findings from Bayer Provides New Data on Contraceptives (Evaluation of a..
06/15 BAYER : Patent Issued for Inserter (USPTO 9668912)
06/15 BAYER : $27,600 Federal Contract Awarded to NovaMed
06/14 DGAP-AFR : Covestro AG: Preliminary announcement of the publication of financial..
06/13 Hydrogenated MDI Market 2017 - DSM, BASF, Covestro, Ashland, Vencorex, Rohm &..
More news
Sector news : Pharmaceuticals - NEC
06:27p MYLAN : shareholders vote against executive pay, re-elect board
10:57a Oil keeps a lid on European shares, Novartis drives health stocks
08:48aDJR. JOHNSON : Missouri Sues Drug Firms Over Opioid Marketing -- WSJ
06/21 Healthcare stocks rally as Senate set to unveil bill
06/21DJJOHNSON & JOHNSON : J&J Seeking Dismissal of Talc Lawsuits in Missouri
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06/20 Novartis wet AMD candidate brolucizumab matches Eylea in late-stage studies w..
06/18 MONSANTO : Majority Of Polled Americans Oppose Bayer Acquisition (Will It Matter..
06/14 New Triple-Digit Dividend Record + Projection Tool For My 74 Stock Portfolio ..
06/12 BLOOMBERG : BASF, Syngenta among bidders for Bayer-Monsanto assets
06/09 Price-To-Sales Ratio Shows Regeneron Is A Bargain
Financials (€)
Sales 2017 49 998 M
EBIT 2017 9 698 M
Net income 2017 5 742 M
Debt 2017 10 783 M
Yield 2017 2,35%
P/E ratio 2017 18,51
P/E ratio 2018 17,22
EV / Sales 2017 2,23x
EV / Sales 2018 2,07x
Capitalization 100 722 M
More Financials
Duration : Period :
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Full-screen chart
Technical analysis trends BAYER
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 118 €
Spread / Average Target -3,1%
Consensus details
EPS Revisions
More Estimates Revisions
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BAYER22.87%112 101
JOHNSON & JOHNSON16.50%361 566
ROCHE HOLDING LTD.8.81%224 305
NOVARTIS7.69%214 091
PFIZER4.31%199 854
MERCK AND COMPANY11.19%176 500
More Results